Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Research Antibodies Market Worth $4.30 Billion By 2025 | CAGR 6.1%: Grand View Research, Inc.

This image opens in the lightbox

News provided by

Grand View Research, Inc.

11 Apr, 2018, 09:45 GMT

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, April 11, 2018 /PRNewswire/ --

The global research antibodies market size is expected to reach USD 4.30 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.1% during the forecast period. The market is predominantly driven by growing number of R&D collaborations among various public and private organizations to promote technical advancements in product development activities and disease progression studies. Consistent recommendations and guidelines issued by regulatory organizations for laboratories to facilitate generation of accurate results and ensure high-quality standards are slated to enhance adoption of research antibodies over the coming years. For instance, in May 2016, the International Society for Stem Cell Research issued revised guidelines for cell-based therapies. The revised guidelines were issued with a focus to improve overall efficiency and quality of preclinical studies.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

In addition, prominent market players are entering into partnership with R&D entities that are anticipated to open new avenues. In December 2016, Bayer AG and Versant Ventures collaborated to invest around USD 225.0 million for the establishment of a stem cell research facility in Canada to encourage commercialization of regenerative medicine therapies. Increasing prevalence of breast cancer and soaring need for personalized medicine is stirring up the demand for advanced techniques, which in turn is creating ample growth opportunities for the research antibodies market.

Browse full research report with TOC on "Research Antibodies Market Size, Share & Trends Analysis Report By Product, By Type (Monoclonal, Polyclonal), By Technology, By Source, By Application (Oncology, Neurobiology), By End-use, And Segment Forecasts, 2018 - 2025" at: https://www.grandviewresearch.com/industry-analysis/research-antibodies-market

Further Key Findings From the Report Suggest: 

  • Primary antibodies were the most prominent product segment in 2016 owing to greater specificity leading to increased adoption in research activities. The segment is expected to account for more than 65.0% of the overall market revenue by 2025
  • On the basis of type, monoclonal antibodies captured substantial share of the market in 2016, owing to high sensitivity for detection of antigens and efficient staining properties with less background noise. The segment is anticipated to rise at a CAGR of 6.6% during the forecast period
  • Western blotting commanded the leading share in the market, due to benefits such as better immunogenic response from infectious agents and higher cost efficiency. The immunoprecipitation segment is estimated to post the highest CAGR of just over 7.0% during the same period
  • Mouse antibodies are relatively easier to produce and possess greater specificity, thus resulting in higher adoption in R&D and accounting for the largest market share in 2016.
  • Oncology accounted for over 36.0% of the overall revenue in 2016 as a consequence of growing cancer population
  • Pharmaceutical & biotechnology companies will be the leading end users of research antibodies owing to increased adoption in drug development and discovery. The segment is poised to represent more than 61.0% of the overall revenue by 2025.
  • Contract research organizations are likely to be the most promising end-user segment during the forecast period owing to greater cost efficiency
  • North America will continue to be the dominant revenue contributor throughout the forecast period owing to local presence of various biotechnology & biopharmaceutical manufacturers striving to compete in the market
  • Some of the key players in the global arena are Abcam PLC; Agilent Technologies; and Thermo Fisher Scientific, Inc. The research antibodies market is moderately consolidated and highly competitive due to low entry barriers.

Browse related reports by Grand View Research: 

  • Clinical Diagnostics Market - Disease management and increasing demand for lab automation are the key drivers of clinical diagnostics market.
  • Aptamers Market - The global aptamers market size was valued at USD 723.6 million in 2016 and is projected to grow at a CAGR of 28.2% during the forecast period.
  • Stem Cells Market - The global stem cells market size was estimated at USD 6.87 billion in 2016. 
  • Molecular Biology Enzymes And Kits & Reagents Market - The global Molecular Biology Enzymes And Kits & Reagentsmarket size was valued at USD 5.77 billion in 2016 and is expected to witness a CAGR of 19.0% 

Grand View Research has segmented the global research antibodies market on the basis of product, type, technology, source, application, end-use, and region: 

  • Research Antibodies Product Outlook (Revenue, USD Million, 2014 - 2025) 
    • Primary
    • Secondary
  • Research Antibodies Type Outlook (Revenue, USD Million, 2014 - 2025) 
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Research Antibodies Technology Outlook (Revenue, USD Million, 2014 - 2025) 
    • Immunohistochemistry
    • Immunofluorescence
    • Western Blotting
    • Flow Cytometry
    • Immunoprecipitation
    • ELISA
    • Others
  • Research Antibodies Source Outlook (Revenue, USD Million, 2014 - 2025) 
    • Mouse
    • Rabbit
    • Goat
    • Others
  • Research Antibodies Application Outlook (Revenue, USD Million, 2014 - 2025) 
    • Infectious Diseases
    • Immunology
    • Oncology
    • Stem Cells
    • Neurobiology
    • Others
  • Research Antibodies End-use Outlook (Revenue, USD Million, 2014 - 2025) 
    • Academic & Research Institutes
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
  • Research Antibodies Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      •  Canada
    • Europe
      • U.K.
      •  Germany
    • Asia Pacific
      • Japan
      • China
      •  India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Modal title

Also from this source

Vineet Agarwal Joins Grand View Research as Investor and Board Member

Vineet Agarwal Joins Grand View Research as Investor and Board Member

We are pleased to announce that Vineet Agarwal, a seasoned business leader and investor with over 20 years of experience in strategy, research &...

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

Grand View Research's Latest Market Research Findings Predict Major Shifts in Flooring Market by 2030

The global flooring market size is estimated to reach USD 534.6 billion by 2030, registering a CAGR of 6.8% from 2025 to 2030, according to a new...

More Releases From This Source

Explore

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.